In the last three months, 19 analysts have published ratings on Alnylam Pharmaceuticals ALNY, offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 9 | 7 | 3 | 0 | 0 |
| Last 30D | 0 | 0 | 0 | 0 | 0 |
| 1M Ago | 8 | 5 | 2 | 0 | 0 |
| 2M Ago | 1 | 2 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $406.0, a high estimate of $550.00, and a low estimate of $333.00. This current average reflects an increase of 20.04% from the previous average price target of $338.22.
Breaking Down Analyst Ratings: A Detailed Examination
The perception of Alnylam Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Greg Harrison | Scotiabank | Raises | Sector Outperform | $450.00 | $342.00 |
| Eliana Merle | UBS | Raises | Buy | $550.00 | $403.00 |
| Whitney Ijem | Canaccord Genuity | Raises | Buy | $415.00 | $390.00 |
| Tiago Fauth | Wells Fargo | Raises | Equal-Weight | $395.00 | $333.00 |
| Martin Auster | Raymond James | Raises | Outperform | $424.00 | $370.00 |
| Gena Wang | Barclays | Raises | Overweight | $460.00 | $329.00 |
| Edward Tenthoff | Piper Sandler | Raises | Overweight | $449.00 | $304.00 |
| Keay Nakae | Chardan Capital | Raises | Buy | $400.00 | $325.00 |
| Michael Ulz | Morgan Stanley | Raises | Equal-Weight | $405.00 | $312.00 |
| Joseph Stringer | Needham | Raises | Buy | $478.00 | $377.00 |
| Danielle Brill | Truist Securities | Announces | Buy | $385.00 | - |
| Jessica Fye | JP Morgan | Raises | Overweight | $348.00 | $338.00 |
| David Lebovitz | Citigroup | Raises | Buy | $404.00 | $364.00 |
| Tazeen Ahmad | B of A Securities | Raises | Buy | $359.00 | $336.00 |
| Maury Raycroft | Jefferies | Raises | Buy | $384.00 | $328.00 |
| Tiago Fauth | Wells Fargo | Raises | Equal-Weight | $333.00 | $287.00 |
| Joseph Stringer | Needham | Raises | Buy | $377.00 | $320.00 |
| Kostas Biliouris | BMO Capital | Raises | Outperform | $360.00 | $300.00 |
| Jessica Fye | JP Morgan | Raises | Overweight | $338.00 | $330.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Alnylam Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Alnylam Pharmaceuticals compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Alnylam Pharmaceuticals's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Capture valuable insights into Alnylam Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Alnylam Pharmaceuticals analyst ratings.
Unveiling the Story Behind Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Alnylam Pharmaceuticals's Economic Impact: An Analysis
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Positive Revenue Trend: Examining Alnylam Pharmaceuticals's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 17.26% as of 30 June, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Alnylam Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -8.57%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Alnylam Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -36.21%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Alnylam Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.51%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 5.18, caution is advised due to increased financial risk.
What Are Analyst Ratings?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
